Markets › India › NSE › CONCORDBIO

Concord Biotech Ltd

NSE:CONCORDBIOHealthcareNSE:CNX500NSE:NIFTY500_EW

₹1,285.80−3.97%At closeAt close · Mon 19 Oct · ≈ AED 49.68 · Market cap $1.47B · Next earnings Wed 18 Nov

Ratio	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	Current · undated	YoY
Gross margin	81.0%	75.9%	77.5%	65.6%	64.0%	41.9%	—	—
Operating margin	69.7%	58.4%	60.7%	51.3%	50.2%	27.8%	27.8%	+0.0 pts
Net margin	38.1%	24.5%	28.1%	30.3%	31.0%	24.7%	24.7%	+0.0 pts
EBITDA margin	53.3%	39.0%	41.3%	43.1%	42.7%	39.8%	—	—
Return on equity	23.5%	15.9%	18.6%	20.2%	20.5%	12.9%	12.9%	+0.0 pts
Return on assets	19.9%	13.3%	15.9%	18.1%	18.3%	11.7%	11.7%	+0.0 pts
Return on capital employed	39.9%	36.0%	39.2%	33.4%	32.5%	14.2%	—	—
Debt / equity	0.1×	0.1×	0.0×	0.0×	0.0×	0.0×	0.0×	+0.1%
Debt / assets	7.6%	4.8%	2.1%	0.6%	0.1%	0.1%	—	—
Interest coverage	475.4×	67.8×	56.7×	166.7×	577.9×	1,034.4×	—	—
Current ratio	5.7×	4.1×	3.8×	6.3×	6.2×	7.4×	7.4×	+0.0%
Quick ratio	4.3×	2.8×	2.7×	4.8×	4.9×	5.5×	—	—
Cash ratio	0.0×	0.0×	0.0×	0.1×	0.0×	0.1×	0.1×	+0.0%
Asset turnover	0.5×	0.5×	0.6×	0.6×	0.6×	0.5×	—	—
Inventory turnover	0.8×	0.9×	0.9×	1.7×	1.8×	1.9×	—	—
Receivables turnover	2.9×	2.7×	2.7×	2.9×	2.3×	2.3×	—	—
Dividend payout	2.4%	40.3%	22.3%	23.2%	24.6%	42.9%	—	—

Margins, returns, leverage and liquidityUpdated Tue 31 Mar ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.